Last reviewed · How we verify

Donepezil 5 mg

Centre Hospitalier St Anne · FDA-approved active Small molecule Quality 2/100

Donepezil 5 mg is a Small molecule drug developed by Centre Hospitalier St Anne. It is currently FDA-approved. Also known as: Donepezil chlorhydrate, Aricept, E2020.

At a glance

Generic nameDonepezil 5 mg
Also known asDonepezil chlorhydrate, Aricept, E2020
SponsorCentre Hospitalier St Anne
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Donepezil 5 mg

What is Donepezil 5 mg?

Donepezil 5 mg is a Small molecule drug developed by Centre Hospitalier St Anne.

Who makes Donepezil 5 mg?

Donepezil 5 mg is developed and marketed by Centre Hospitalier St Anne (see full Centre Hospitalier St Anne pipeline at /company/centre-hospitalier-st-anne).

Is Donepezil 5 mg also known as anything else?

Donepezil 5 mg is also known as Donepezil chlorhydrate, Aricept, E2020.

What development phase is Donepezil 5 mg in?

Donepezil 5 mg is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing